Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Topical KX-826 in Chinese Male Patients With Androgenetic Alopecia
NCT06622824Phase 3Not yet recruiting
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pyrilutamide in androgenetic alopecia (AGA) (3 arms), sponsored by Kintor Pharmaceutical Limited. Primary endpoint: Target Area Non-vellus Hair Count change from baseline at 24 weeks. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06622824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622824.